|Day Low/High||60.82 / 61.85|
|52 Wk Low/High||47.97 / 64.86|
Pro investors have been piling into these five stocks in the third quarter. Here's everything you need to know.
Johnson & Johnson (JNJ), McKesson (MCK), Merck (MRK) and UnitedHealth (UNH) benefit from demographic trends and have solid fundamentals.
Health care stocks in general are under pressure until after the U.S. presidential election, Cramer says.
A day after winning approval for a cancer drug, Merck posts earnings and sales that beat consensus estimates.
The group's Keytruda immunotherapy boosts pharmaceuticals sales.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2016.
On Tuesday, October 25, Apple reports fiscal fourth quarter results after the markets close.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
Here's your 'silver linings playbook' for what promises to be a nerve-wracking week of unpredictable politics, mixed corporate earnings and volatile energy prices.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.
Merck's (MRK) Keytruda treatment improved the survival rate of patients with bladder cancer who previously underwent treatment.
The drug titan reports Tuesday. Will a Dec. 24 cancer drug approval be an early Christmas gift?
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in patients...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Merck Research Laboratories (MRL) facilities in Rahway, N.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of Biosimilars Clarified ( www.
Here are Thursday's top research calls, including upgrades for Anadarko Petroleum, GrubHub and Merck, and a downgrade for Pfizer.
Merck's (MRK) stock rating was increased to 'buy' at BofA/Merrill Lynch earlier today.
Product recalls in different industries exert varying degrees of effects on company stock prices.
Wall Street sells off as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season and crude oil retreats from highs.
Stock losses accelerate on Tuesday afternoon as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season.
U.S. stocks are higher Monday thanks to a rally in crude oil.
The stock's healthy recent pattern appears to be giving way to a fresh bull leg.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
U.S. stocks rose Monday as Wall Street looked past Sunday night's bitter presidential debate, focusing instead on oil's 3% rally and the looming start of earnings season.